UK:
Mulryne Quoted In The Pink Sheet On Brexit Ramifications For Pharmaceutical Industry
16 April 2019
Arnold & Porter
To print this article, all you need is to be registered or login on Mondaq.com.
Life Sciences and Healthcare Regulatory partner Jacqueline Mulryne was quoted in
a recent Pink Sheet article, "Pharma Uncertainty Remains As UK
Votes To Delay Brexit." The article considers how UK-based
life sciences companies can prepare for the UK's departure from
the EU despite uncertainty surrounding the UK's unconfirmed
exit deal.
» Read the full article (subscription
required).
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from UK
Elderly Care FAQ
Wrigleys Solicitors
These FAQs cover topics related to caring for elderly relatives. It discusses how to place an elderly person in a care home, the absence of legal obligation for family members to provide long-term care...
Food Law | UK Regulatory Outlook March 2024
Osborne Clarke
Scotland launches consultation on stricter HFSS restrictions | FSA launch campaign on allergy risks with vegan labelling | Consultation launched on fairer food labelling...